Enoblituzumab, previously known as TJ-271 or MGA271, represents the novel monoclonal directed at CD33, a antigen found predominantly on myeloid tissues. This agent operates as a dual-action therapy, concurrently https://www.targetmol.com/compound/enoblituzumab